These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 23422148

  • 1. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O.
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [Abstract] [Full Text] [Related]

  • 2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.
    Cancer Res; 2008 Oct 01; 68(19):7905-14. PubMed ID: 18829547
    [Abstract] [Full Text] [Related]

  • 3. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 4. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B, Wagenaar E, Tang SC, Schinkel AH.
    Mol Pharm; 2011 Apr 04; 8(2):571-82. PubMed ID: 21309545
    [Abstract] [Full Text] [Related]

  • 5. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.
    Cancer Res; 2011 Apr 15; 71(8):3029-41. PubMed ID: 21402712
    [Abstract] [Full Text] [Related]

  • 6. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 7. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2013 Apr 15; 19(8):2084-95. PubMed ID: 23461902
    [Abstract] [Full Text] [Related]

  • 8. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y.
    Drug Metab Dispos; 2007 Jul 15; 35(7):1142-8. PubMed ID: 17446265
    [Abstract] [Full Text] [Related]

  • 9. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 10. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.
    Biochem Pharmacol; 2013 Feb 15; 85(4):514-24. PubMed ID: 23261525
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2019 Sep 03; 16(9):3842-3852. PubMed ID: 31329454
    [Abstract] [Full Text] [Related]

  • 12. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 03; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 13. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.
    Mol Cancer Ther; 2012 Sep 03; 11(9):2033-44. PubMed ID: 22778153
    [Abstract] [Full Text] [Related]

  • 14. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.
    J Natl Cancer Inst; 2000 Oct 18; 92(20):1651-6. PubMed ID: 11036110
    [Abstract] [Full Text] [Related]

  • 15. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 18; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 16. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 17. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
    Gardner ER, Smith NF, Figg WD, Sparreboom A.
    J Exp Clin Cancer Res; 2009 Jul 10; 28(1):99. PubMed ID: 19591692
    [Abstract] [Full Text] [Related]

  • 18. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
    Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S.
    Cancer Res; 2010 Feb 15; 70(4):1700-10. PubMed ID: 20145144
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
    Chen Y, Bieber MM, Teng NN.
    Mol Carcinog; 2014 Aug 15; 53(8):625-34. PubMed ID: 23423781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.